Glamhive Founder Stephanie Sprangers and Celebrity Stylist Jennifer Rade Announce Digital Fall Style and Beauty Summit
6.11.2020 17:07:00 EET | Business Wire | Press release
Glamhive announced its third online conference to be held on November 14. The Glamhive Digital Fall Style and Beauty Summit will bring together top fashion and beauty leaders, from Sarah Jessica Parker's stylist to Kim Kardashian's hairstylist. The innovative leaders will discuss all things fashion, wellness, beauty, and more. Stephanie Sprangers and Jennifer Rade will co-host the event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201106005072/en/
The Glamhive Digital Fall Style and Beauty Summit will bring together top fashion and beauty leaders (Graphic: Mary Kay Inc.)
"I'm excited to co-host the Glamhive LIVE Fall Style and Beauty summit with Stephanie. We're bringing together the most amazing stylists, makeup artists, hairstylists, designers, & entrepreneurs in the world to share everything we've learned—from how we got started to all our tips and tricks on how to have great personal style," said Jennifer Rade, celebrity stylist and costume designer. Jennifer is one of the busiest stylists working today. Her clientele has ranged from A-List stars Angelina Jolie, Abbie Cornish, Cher, and Jenna Fischer, to musicians Lady A, Pink, Marilyn Manson, Dave Matthews, Amy Winehouse, Motley Crue, and Tina Turner. Her work has been featured in many publications, including W, Vanity Fair, Marie Claire, GQ, Esquire, and Harper's Bazaar.
"Glamhive's vision is to make personal styling available to everyone, everywhere, and our digital events are a wonderful extension of that. This year has enabled us to bring our events to everyone, everywhere so that people who are fashion and beauty enthusiasts or work in the industry can learn from the best in the business," said Stephanie Sprangers, Glamhive founder. Sprangers is the Founder and Chief Executive Officer of Glamhive, the online personal styling service that brings expert personal stylists and makeup artists—recruited directly from Hollywood and Instagram—to everyone. Glamhive has developed proprietary software that allows stylists to take clients through a styling experience that is 100% online, allowing people to work with stylists anywhere in the world.
The all-day, ticketed event will feature 22 segments with 50-plus speakers. Below is an overview of some of the topics that will be covered by their all-star speaker line-up.
TOPICS:
- Zoom Style: Having Great (and Comfortable) Style
- The Making of a Fashion Stylist
- Foundations First
- How Your Home Environment Impacts Your Mood and Reflects Your Style
- How to Build the Wardrobe of Your Dreams
- 360 Style -- The Interplay of Hair, Makeup, and Wardrobe
- Entrepreneurship -- The Courage to Go For Your Dreams
- Future of the Red Carpet
- French Girl Chic and Our Obsession with Emily in Paris
- Shape Matters -- Love Yourself and Your Shape
- Style Your Health - Boosting Your Energy and Immunity
- Skincare Basics: Coaching Clients on Self-Care
- Iconic Style + How to Make a Statement with Your Style
SPEAKERS:
Speakers include celebrity stylists, makeup artists, image-makers who work with the biggest names in Hollywood and beyond, including:
Angelina Jolie, Mandy Moore, Sarah Jessica Parker, Kristen Bell, Khloe Kardashian, Robert Downey Jr, Keanu Reeves, Dwayne Johnson, Donald Glover, Sharon Stone, Serena Williams, Miranda Lambert, Julianne Moore, Liv Tyler, and more.
CELEBRITY STYLISTS:
Jennifer Rade, Ilaria Urbinati, Erin Walsh, Nicole Chavez, Jeanne Yang, Janelle Miller, Lindsey Dupuis, Tiffany Gifford, Sonia Young, Rachel Wirkus, Kesha McCloud
CELEBRITY MAKEUP ARTISTS + HAIRSTYLISTS:
Danesa Myricks, Andrew Fitzsimons, Daniel Martin, Colleen, Runne, Quinn Murphy, Sheridan Ward, Simedar Jackson, and Mia Santiago
ENTREPRENEURS, DESIGNERS, AND BUSINESS LEADERS
Cindy Eckhert (The Pink Ceiling Fund), Jonathan Sposato (Founder, PicMonkey), Carrie Colbert (Curated Capital), Summer Holl (President, Elyse Walker), Christian Juul Nielsen (Herve Leger | Aknvas), Lucy Aylen (Never Fully Dressed), Dr. Shrereene Idress, Dr. Avanti Kumar Singh
MODERATORS:
Brian Underwood (O the Oprah Magazine), Brooke Jaffe (former Fashion Director, Bloomingdales), Jack Eustace, Nicole Young (E! News), Kibwe Chase Marshall, Co-Founder, The Kelly Initiative), Jezlan Moyet.
Tickets to the conference are $99 for an all-day ticket and include a custom playlist by She-J Nikki Pennie. The presenting sponsor for the Glamhive Digital Fall Style and Beauty Summit is Mary Kay and its Mary Kay Global Design Studio. Other sponsors include NuBra USA, LEO, AKNVAS, NYDJ and more.
For more information, visit www.glamhive.com/upcoming.
About Glamhive
Glamhive was founded by entrepreneur Stephanie Sprangers in 2017 with the vision to democratize personal styling and the premise that the confidence that comes with glamour should not be exclusive to the rich and famous.
The online styling experience offers anyone with a WiFi connection access to stylists who will provide them with the support they need to be the best version of themselves. For stylists, it is a seamless end-to-end platform to help them grow their network and their business, 100% virtually.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201106005072/en/
Contact information
Stephanie Sprangers, Founder + CEO, Glamhive
stephanie@glamhive.com
+1.206.851.0446
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
